ImmuneOncia: No Revenue, Expanding Operating Loss in Q1 2026, Rights Offering Decided

Q1 2026 revenue: 0 won (vs 51.8 million won in Q1 2025), operating loss 5.75 billion won (loss widened 26%)
Net loss 5.62 billion won, accumulated deficit 143.7 billion won
Cash and cash equivalents 8.9 billion won + short-term financial instruments 10.1 billion won; liquidity secured
IMC-001 phase 2 for NK/T-cell lymphoma: ORR 79%, orphan drug designation obtained in January 2026
IMC-002 (anti-CD47) in phase 1b, targeting global out-license
February 2026: rights offering of 16.83 million shares at 4,860 won per share, payment due May 2026
Major shareholder Yuhan (65.75%) collaborating on domestic commercialization of IMC-001